FDA — authorised 11 March 1964
- Marketing authorisation holder: BAXTER HLTHCARE CORP
- Status: approved
🇺🇸 Pralidoxime Chloride (Autoinjector) in United States
FDA authorised Pralidoxime Chloride (Autoinjector) on 11 March 1964
Marketing authorisations
FDA — authorised 26 April 1983
- Application: NDA018986
- Marketing authorisation holder: MERIDIAN MEDCL TECHN
- Local brand name: PRALIDOXIME CHLORIDE (AUTOINJECTOR)
- Indication: SOLUTION — INTRAMUSCULAR
- Status: approved
Pralidoxime Chloride (Autoinjector) in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Neuroscience approved in United States
Frequently asked questions
Is Pralidoxime Chloride (Autoinjector) approved in United States?
Yes. FDA authorised it on 11 March 1964; FDA authorised it on 26 April 1983.
Who is the marketing authorisation holder for Pralidoxime Chloride (Autoinjector) in United States?
BAXTER HLTHCARE CORP holds the US marketing authorisation.